ANAMNESTIC CLINICAL-PSYCHOPATHATOLOGICAL FEATURES OF DEPRESSIVE MANIFESTATIONS IN PATIENTS WITH COGNITIVE IMPAIRMENTS IN DEPRESSIVE DISORDERS
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2020.3.11347Keywords:
patients with cognitive impairment, depressive disorders, clinical and psychopathological features, recurrent depressive disorder, bipolar depressive disorder, prolonged depressive reactionAbstract
Summary. The urgency of the problem of depression is due not only to the prevalence and maladaptive effects, but also the fact that timely diagnosis of these disorders in many cases becomes a crucial condition for successful medical care, so research to study the anamnestic data on the onset of depression and the duration of the disease in patients with cognitive impairment in various types of depressive disorders is relevant and will improve the criteria for diagnosis and improve the effectiveness of treatment.
The aim of the study – to determine the anamnestic clinical and psychopathological features of depressive manifestations in patients with cognitive impairment in depressive disorders.
Materials and Methods. 362 patients with cognitive impairment in depressive disorders were examined: 123 patients with recurrent depressive disorder (RDD), 141 patients with bipolar affective disorder (BAD) and 98 patients with prolonged depressive reaction (PDR). A set of research methods was used: clinical-psychopathological, clinical-anamnestic and statistical.
Results. Specific features of the course of depressive disorder in patients with cognitive impairment in different types of depressive disorders were established: in RDD there was a predominance of subacute and prolonged onset of depression; duration of a depressive episode from 3 to 6 months; predominance of 3–5 and 1–2 episodes in the anamnesis; duration of remission from 12 to 24 months. The predominance of acute and subacute onset of depression was noted in BAD; duration of a depressive episode from 6 months to 1 year; predominance of 3–5 or more 5 episodes in the anamnesis; duration of remission from 6 to 12 months; in patients with PDR the prevalence of the long and subacute beginning of depression was noted; duration of a depressive episode "up to a year", "up to 1.5 years" and "up to 2 years"; predominance of 1–2 episodes in the anamnesis; duration of remission more than 24 months.
Conclusions. The study identified the features of the course of depressive disorder in patients with cognitive impairment in different types of depressive disorders, which can act as diagnostic criteria in the differential diagnosis and be targets for pharmacotherapy and social rehabilitation.
References
Comprehensive mental health action plan 2013–2020. [Electronic resource]. Geneva: WHO, 2013. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_R8-ru.pdf?ua=1 Russian.
Marcus M, Yasamy MT, van Ommeren M. Depression: a global public health concern. Geneva, Switzerland: World Health Organization, 2012.
Bedlinsky VO [Comparative characteristic of depression in ailments, who have suffered cranio-cerebral trauma, and in patients with endogenous affective disorders of the mood]. Arkhiv psykhiatrii. 2017;23: 33-6. Ukrainian.
Barton B. Die depressive Symptomatik muss "übersetzt" warden. DNP-Der Neurologe & Psychiater. 2017;18(3): 35-44. DOI: https://doi.org/10.1007/s15202-017-1598-6. DOI: https://doi.org/10.1007/s15202-017-1598-6
Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11: 875-88.
Eschweiler GW. Diagnostik und multimodale Therapie der Altersdepression: Diagnostics and multimodal treatment of depression in old age. Zeitschrift für Gerontologie und Geriatrie. 2017;50(2): 99-105. DOI: 10.1007/s00391-016–1174-2. DOI: https://doi.org/10.1007/s00391-016-1174-2
Maslow GR, Dunlap, RJ. Chung K. Depression and suicide in children and adolescents. Pediatr Rev. 2015;36(70): 299-308; quiz 9-10. Epub 2015/07/03. DOI: 10.1542/pir. 36-7–299.
Khin N, Chen Y, Yang Y, Yang P, Laughren T. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011;72(4): 464-72. DOI: https://doi.org/10.4088/JCP.10m06191
Westen D. Prototype diagnosis of psychiatric syndromes. World Psychiatry 2012;11: 12-21. DOI: https://doi.org/10.1016/j.wpsyc.2012.01.004
Maruta NO, Panko TV, Kalenska GYu. [Diagnostic criteria for depressive disorders at stages of providing medical aid]. Ukrainskyi visnyk psykhonevrolohii. 2017;25:1(90): 135. Ukrainian.
Corp SA, Gitlin MJ & Altshuler LL A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry. 2014;75: 1010-18. DOI: https://doi.org/10.4088/JCP.13r08851
Maruta NA, Yavdak IA, Cherednyakova ES. [Neurotrophic therapy for depression: opportunities and prospects]. Mezhdunarodnyy nevrologicheskiy zhurnal. 2014;4(66): 70-9. Russian. DOI: https://doi.org/10.22141/2224-0713.4.66.2014.80614
Greer TL, Dunderajan P, Grannemann BD, Kurian BT, Trivedi MH. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depress Res Treat. 2014: 1-13. DOI: https://doi.org/10.1155/2014/627863
